Compare ACADIA Pharmaceuticals Inc. (ACAD) vs CVS Health Corp (CVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs CVS Health Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while CVS Health Corp trades at $104.47 (market cap $133.12B). The key difference: CVS Health Corp is far larger — about 29.6× ACADIA Pharmaceuticals Inc.'s market cap, and CVS Health Corp pays a 2.55% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CVS | |
|---|---|---|
Market Cap | $4.49B | $133.12B |
Sector | Health | Health |
52-Week High | $28.06 | $104.81 |
52-Week Low | $20.06 | $58.75 |
Enterprise Value | $3.69B | $199.66B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CVS Health trades at $104.33, down slightly on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates, including a recent Q1 2026 beat, and benefits from positive sentiment around strategic initiatives like GLP-1 drug access. Revenue growth remains solid, though net margins are thin. The current price sits just below the consensus price target of $106.86.
The outlook for CVS is positive, driven by earnings momentum and strategic positioning in healthcare services. Key opportunities include margin expansion potential and market share gains. Risks involve intense competition, regulatory pressures on healthcare pricing, and the company's significant debt load, which requires careful management of cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
